ClinicalTrials.Veeva

Menu

Bioequivalence Study of Letrozole 2.5 mg Tablets

Y

Yuhan

Status

Completed

Conditions

Healthy

Treatments

Drug: Femara (Sequence 1)
Drug: Peratra (Sequence 2)
Drug: Femara (Sequence 2)
Drug: Peratra (Sequence 1)

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

Bioequivalence

Full description

The purpose of this study was to determine the bioequivalence of letrozole 2.5 mg tablets after administration of single doses to normal healthy Korean subjects under fasted conditions.

Enrollment

26 patients

Sex

Male

Ages

19 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male volunteers in the age between 19 to 55 years old
  • Subjects were neither congenital nor chronic diseases.
  • Subjects were selected after passing a clinical screening procedure that included a physical examination and laboratory tests.
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements, as evidenced by a signed Informed Consent Form.

Exclusion criteria

  • Any history of a clinical condition which might affect drug absorption, distribution, metabolism or excretion or might be risk factors, e.g. clinically significant disorder in heart, liver, respiratory system, liver, kidney, gastrointestinal system and CNS
  • Had a history of myocardial infarction, stroke, hypertension, arrhythmia, coronary artery disease, disease of neuropsychiatry, gastrointestinal system surgery (excluding appendectomy, herniotomy)
  • Current clinically significant disorder in history taking or physical examination
  • Acute disease within 14 days preceding the first application of study medication
  • Had an relevant allergic disease
  • Had history of hypersensitivity to drugs or any food
  • Positive for Hepatitis B antigen, Hepatitis C antibody, HIV antibody, or High Quality Syphilis Reagin Test
  • Excessive caffeine, alcohol intake and smoker(caffeine>5 units/day, alcohol>3 units/day(1 unit = pure alcohol 10ml), cigarettes> 20 cigarettes /day)
  • Subjects who excessive alcohol intake or drug which affect drug metabolism enzyme intake within 30 days preceding study
  • History of drug abuse or positive for urinary testing of drugs abuse (amphetamine, barbiturates, cocaine, opioids, benzodiazepines etc.)
  • Has donated whole blood within 60days or apheresis within 14days preceding the first application of study medication
  • Received other investigational drug within 60days preceding the first application of study medication
  • Taken any herbal medicine within 30days, prescription medication within 14 days or over-the-counter drug (except for vitamins, minerals) within 10days preceding the first application of study medication (might affect this study or safety of subjects as judged by the investigator)
  • Subjects couldn't eat ASAN MEDICAL CENTER standard meal or were unsuitable for this study as judged by investigators

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

26 participants in 2 patient groups

Femara First, Then Peratra (Sequence 1)
Experimental group
Description:
Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.
Treatment:
Drug: Peratra (Sequence 1)
Drug: Femara (Sequence 1)
Peratra First, Then Femara (Sequence 2)
Experimental group
Description:
Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.
Treatment:
Drug: Femara (Sequence 2)
Drug: Peratra (Sequence 2)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems